HUTCHMED says Phase III ESLIM-02 trial shows sovleplenib lifts durable response in warm autoimmune hemolytic anemia

• HUTCHMED highlighted Phase III results for sovleplenib in warm autoimmune hemolytic anemia, already presented at the EHA 2026 Congress on June 11.
• The trial showed the drug delivered faster, more sustained improvement in hemoglobin control than placebo, with fewer relapses and less need for rescue treatment.
• Patients on sovleplenib also required fewer blood transfusions and were more likely to reduce or stop background steroid use.
• Safety was described as favorable, with fewer severe adverse events than placebo and no treatment-related deaths or discontinuations reported.
• China’s NMPA accepted an NDA for sovleplenib in April 2026, granting priority review for adults with inadequate response to prior glucocorticoids.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606112000PRIMZONEFULLFEED9745650) on June 12, 2026, and is solely responsible for the information contained therein.